CRNX
Crinetics Pharmaceuticals Inc
85.00$
+0.0%
vs. previous close
Closing price · As of: Sep 2, 2026
Statements
Cash Flow
Crinetics Pharmaceuticals Inc (CRNX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -94 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.5 | -2.3 | -2.2 | -2.4 | -2.5 | -3.4 | -4.4 | -5.7 | -6.0 | -6.8 | -13 | -14 | -13 | -12 | -16 | -18 | -16 | -20 | -20 | -26 | -23 | -14 | -28 | -38 | -35 | -41 | -46 | -41 | -39 | -53 | -48 | -61 | -65 | -88 | -86 | -111 | -93 | -125 | -94 | -423 | |
| 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.2 | 0.3 | 0.2 | 0.2 | 0.3 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.2 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.5 | 0.8 | 0.8 | 0.8 | 0.9 | 1.0 | 1.0 | 1.0 | 1.2 | 1.1 | 4.2 | |
| – | 0.1 | 0.1 | 0.1 | 0.1 | 0.4 | 0.3 | 0.8 | 0.8 | 1.0 | 1.6 | 1.9 | 1.8 | 2.1 | 2.5 | 2.8 | 3.0 | 3.4 | 4.2 | 4.6 | 5.2 | 5.8 | 7.1 | 7.4 | 7.9 | 8.1 | 10 | 11 | 12 | 13 | 19 | 18 | 19 | 20 | 26 | 23 | 22 | 30 | 25 | 99 | |
| 0.3 | 0.1 | 0.1 | 0.1 | 0.3 | 0.4 | 0.3 | 0.8 | 0.4 | 1.0 | 1.6 | 1.9 | 1.8 | 2.1 | 2.5 | 2.8 | 3.1 | 3.4 | 4.4 | 4.6 | 4.3 | 6.8 | 7.4 | 7.4 | 7.1 | 8.1 | 9.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 0.2 | -0.6 | -0.2 | -0.1 | 1.6 | 0.9 | 1.0 | 1.9 | 1.4 | -1.7 | -1.0 | -0.8 | 2.9 | -2.1 | -2.8 | 2.4 | -1.0 | 1.5 | -2.8 | 3.3 | 14 | 6.8 | -4.2 | 2.4 | -0.7 | -4.4 | 4.9 | 8.3 | 2.7 | 9.4 | -0.1 | -0.3 | -9.5 | 6.6 | -1.5 | 9.3 | -26 | 2.0 | -16 | |
| 0.2 | 0.0 | 0.0 | 0.0 | 0.2 | 0.1 | 0.5 | 0.3 | 0.3 | 0.4 | 0.1 | 0.5 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.0 | 0.1 | 0.6 | 0.7 | 0.3 | 0.0 | 0.2 | 3.5 | 0.9 | 1.3 | 1.0 | 0.5 | 1.0 | 1.2 | 3.2 | 0.9 | 0.5 | 0.8 | 0.5 | 2.7 | |
| -0.2 | 0.0 | 0.0 | 0.0 | -0.2 | -0.1 | -0.5 | -0.3 | -119 | 25 | 9.4 | 20 | -13 | 16 | 18 | -25 | -8.9 | 33 | 20 | -7.0 | -102 | -43 | -174 | 6.8 | 37 | 49 | 31 | -193 | -87 | 0.3 | -54 | 21 | -542 | -86 | 38 | 165 | 57 | -252 | 26 | -4.2 | |
| – | – | – | – | – | – | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.1 | 0.1 | – | – | 0.1 | 0.3 | 0.0 | 0.0 | 170 | 0.0 | -0.1 | 0.0 | 0.0 | 6.5 | 108 | -0.2 | 0.1 | 0.1 | 73 | 15 | – | 1.8 | 119 | 1.1 | – | 0.5 | – | – | – | – | – | – | – | 0.0 | – | – | – | -0.6 | – | – | |
| 0.0 | 0.0 | 0.0 | 0.0 | -0.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.1 | 0.1 | 4.7 | 0.0 | 7.1 | 64 | -0.5 | 107 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.5 | 108 | -0.2 | 0.1 | 0.1 | 73 | 15 | 164 | 1.8 | 119 | 1.1 | 0.1 | 0.5 | 13 | 338 | 38 | 394 | 7.5 | 55 | 554 | 4.4 | 7.1 | 3.1 | 26 | 390 | 8.9 | 428 | |
| -5.7 | -2.3 | 2.5 | -2.5 | 4.3 | 60 | -5.3 | 101 | -125 | 18 | -3.1 | 6.9 | -26 | 11 | 110 | -43 | -25 | 12 | 73 | -17 | 39 | -55 | -83 | -31 | 1.8 | 8.5 | -1.6 | 103 | -88 | 341 | -94 | 15 | -53 | -170 | -41 | 57 | -9.9 | 13 | -59 | 1.3 | |
| – | -2.3 | -2.2 | -2.5 | -2.7 | -3.5 | -4.8 | -5.9 | -6.3 | -7.2 | -13 | -14 | -13 | -12 | -16 | -18 | -16 | -20 | -20 | -26 | -23 | -14 | -29 | -39 | -35 | -41 | -46 | -45 | -39 | -54 | -49 | -61 | -66 | -90 | -89 | -112 | -93 | -126 | -95 | -425 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.